With unprecedented understanding of molecular events underlying human cancer in this genomic era, a large number of drugs specifically targeting hypothesized oncogenic drivers to which tumors are potentially addicted to have been developed and continue to be developed. These targeted cancer therapies are being actively tested in clinical trials with mixed successes. This editorial provides an overview on successful targeted cancer drugs on the market and those drugs that are in late clinical development stages.
The first targeted cancer therapy was tamoxifen approved in 1970s. Tamoxifen binds to the estrogen receptor (ER), prevents estrogen from binding to ER, and therefore modulates ER activity. By interfering estrogen爷s ability to stimulate cancer cell growth, tamoxifen provides an effective treatment option for patients with ERpositive breast cancer. Following tamoxifen, multiple ERtargeting drugs were developed to include toremifene, fulvestrant, anastrozole, exemestance, and letrozole, forming the basis of endocrine therapies for ERpositive breast cancer.
In the past two decades, the discovery of oncogenes and tumor suppressor genes, and the completion of human genome sequencing fueled some major advances in our understanding of the molecular mechanisms leading to cancer. Subsequently, such newly emerging biological and genetic information rapidly prompted the introduction of a large number of new targeted cancer therapies.
Signaling pathways regulated by protein kinases are the frequent targets of somatic mutations, leading to many human cancers. Of the more than 100 dominant oncogenes known to date, many encode protein tyrosine kinases. Several mechanisms lead to aberrant function by protein tyrosine kinases and subsequent oncogenic transformation.
These include (1) genomic rearrangements resulting in oncogenic fusion proteins that include the kinase catalytic domain and an unrelated protein that provides a constitutive activation/dimerization function, (2) gainoffunction mutations in the juxtamembrane or kinase domains or small deletions of regulatory regions, (3) overexpression with or without gene amplification, and (4) loss of the normal autoinhibitory and regulatory constraints of kinase activation. At this time, several tyrosine kinase inhibitors of variable target specificity have been approved by the Food and Drug Administration (FDA) for treatment of patients with a variety of cancers (Table 1) .
Several receptor protein and cytoplasmic kinases are known to be mutated and/or overexpressed in human cancer. These include the epidermal growth factor receptor (EGFR; ErbB1), HER2/neu (ErbB2), insulin and insulinlike growth factor (IGF) receptors, fibroblast growth factor receptor2 (FGFR2), FGFR4, Src, ABL, phosphoinositide 3kinase (PI3K), MEK, RAF, among others. In many examples to be reviewed, inactivation of several of these kinases with exogenous inhibitors has resulted in an antitumor effect in preclinical models of cancer. And most importantly, some of these agents have shown promising clinical activity in patients with cancer and are in late development (Table 2) . Several conditions are generally considered prior to the selection of a kinase as a therapeutic target against which drugs are developed. First, the kinase should be a 野gainoffunction冶 oncogene and/or causal to tumor Chinese Journal of Cancer www.cjcsysu.comdevelopment and tumor maintenance. It should be differentially expressed in tumor vs. nontumor tissue and identifiable in cancer tissues. Although the kinase target may have a critical role in postnatal or adult physiology, it should provide a therapeutic window such that 野tumor toxicity冶 occurs before prohibitive host tissue toxicity. Structurefunction knowledge of the molecular target should be in hand in order to develop mechanismbased inhibitors. In general, kinase inhibitors have consisted of neutralizing antibodies, or low molecular weight ATPmimetics and allosteric inhibitors.
Challenges in Targeted Cancer Drug Development
Despite the advancement in targeted therapy, treatment of cancer still remains as a huge unmet medical need. Multiple factors, in addition to the complexity of cancer biology, contribute to this unsatisfactory state.
Lack of reliable preclinical models to predict anti鄄 cancer drug efficacy
Cancer development in human patients is a long multistep process. The resulting malignant tumors are intimately intertwined with surrounding 野normal冶 tissues. Such close tumorhost interactions are vitally important in determining the sensitivity of tumor cells to cancer treatments. However, such complex tumor context is not replicated either or in transgenic or xenograft models. Genetically engineering mouse tumor models provide a potentially promising alternate to assess preclinical cancer drug efficacy. But their true value has yet to be validated by clinical successes. 
Inefficient clinical development

Targeted Cancer Therapies
This table was modified from Targeted cancer therapies by Saurabh Aggarwal [3] . BLA, biologic license application; CML, chronic myeloid leukemia; CTLA4, cytotoxic T鄄 lymphocyte protein 4; EGFR, epidermal growth factor receptor; GIST, gastrointestinal stromal tumor; HER2, human epidermal growth factor receptor 2 (also known as ERBB2); HSP90, heat鄄 shock protein, 90 kDa; IGFR1, insulin鄄 like growth factor receptor 1; MCL1, myeloid cell leukemia sequence 1; mTOR, mammalian target of rapamycin; NDA, new drug application; NSCLC, non-small cell lung cancer; PARP1, poly (ADP鄄 ribose) polymerase 1. Sources: company reports, ClinicalTrials.gov, American Society of Clinical Oncology, American Society of Hematology.
Targeted Cancer Therapies needs, but also stems from the low success rate of cancer medicine development. It is estimated that only 10% of the cancer drug candidates entering clinical stage ultimately gain market approval. New trial approaches are urgently needed especially for the development of targeted cancer therapies that will only benefit a subset of patients. Prospectively identifying sensitive or excluding resistant patient populations to achieve definitive clinical benefit led to successful development of several targeted therapies. Such successes include the use of HER2 fluorescent in situ hybridization (FISH) assay for selecting HER2鄄 positive breast cancer patients receiving Herceptin treatment, EGFR mutation assay for selecting nonsmall cell lung cancer patients to be treated with gefitinib/erlotinib, and applying KRAS mutation assay to avoid exposing colorectal cancer patients with KRAS mutations to antiEGFR mAbs. Recently, such biomarkerbased prospective patient selection strategy was applied to Phase 1 studies to expedite clinical development of several new targeted agents. Overall response rates from 50% to near 80% were achieved in early phase trials of crizotinib (ALK inhibitor), as well as PLX4032 (R7204) and GSK2118436 (bRAF V600E inhibitors). Such dramatic early efficacy data prompted sponsors launching Phase 3 registration trials based on Phase 1 and Phase 2 results (Table 2 ). For compounds lacking definitive biomarkers for identifying sensitive/resistant subpopulation, adaptive trial design to incorporate biomarker identification and validation into one single trial may represent an effective and efficient approach [1] .
Limited single agent activity
Most human tumors harbor numerous mutation events leading to activation of multiple signaling pathways. The redundancy in the signaling systems at the disposal of the cancer cells often render individual targeted agents inactive in treating most cancers. Even in rare exceptions, such as narrowly defined patient populations, single agent activities could be dramatic, but cancers still recur. Combinations of targeted agents represent a potentially effective approach to simultaneously inhibiting multiple pathways, suppressing feedback reactivation of compensatory signaling network, and therefore to prevent recurrence. The parallels between clinical development of combinations and understanding of cancer resistance will ultimately lead to personalized medicine, such as matching targeted therapy with cancer patients based on molecular events underlying their malignancies.
Opportunities for China
The era of targeted cancer therapies brings unique opportunities to China. The already saturated clinical trial density in well established oncology trial regions such as North America and Western Europe poses an impassable challenge to accruing patients with proper molecular characteristics to match targeted agents. For example, nearly 7 000 patients need to be screened to identify the 5% patients with tumors harboring the EML4ALK fusion event for the crizotinib Phase 3 trial of 320 patients. The success in contributing patients to the IPASS trial is a beginning for China to play a more active role in global development of new anticancer agents [2] . In preparation for this new era, it is vital for investigators in China to master the knowledge in new cancer biology, pharmacokinetics, pharmacodynamics, innovative trial design of both early and late phases, as well as to establish core capabilities in molecular testing of tumor samples in real time fashion to support prospective patient selection.
In collaboration with US Chinese AntiCancer Association (USCACA), has organized a series of review articles to cover a broad spectrum of topics in targeted cancer therapies. These articles will analyze each major pathway or target class with an emphasis on mechanism of action, translational medicine, and clinical development. This series of reviews will provide a basis for our readers, especially clinical investigators, to develop a comprehensive appreciation of these targets and pathways in cancer as well as relevant targeted therapies being developed.
